{"id":"https://openalex.org/A5117527428","orcid":"https://orcid.org/0009-0009-8922-9840","observed_orcids":["https://orcid.org/0009-0009-8922-9840"],"display_name":"Mia Lynch","raw_author_names":["Mia Lynch"],"full_name":"Mia Lynch","works_count":8,"cited_by_count":4,"summary_stats":{"2yr_mean_citedness":0.0,"h_index":1,"i10_index":0},"ids":{"openalex":"https://openalex.org/A5117527428","orcid":"https://orcid.org/0009-0009-8922-9840","observed_orcids":["https://orcid.org/0009-0009-8922-9840"]},"affiliations":[{"institution":{"id":"https://openalex.org/I155781252","ror":"https://ror.org/02b6qw903","display_name":"University of South Carolina","country_code":"US","type":"education","lineage":["https://openalex.org/I155781252"]},"years":[2026,2025]}],"last_known_institutions":[{"id":"https://openalex.org/I155781252","ror":"https://ror.org/02b6qw903","display_name":"University of South Carolina","country_code":"US","type":"education","lineage":["https://openalex.org/I155781252"]}],"topics":[{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","count":5,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10746","display_name":"Platelet Disorders and Treatments","count":4,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","count":3,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","count":2,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12352","display_name":"Heparin-Induced Thrombocytopenia and Thrombosis","count":2,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"topic_share":[{"id":"https://openalex.org/T12352","display_name":"Heparin-Induced Thrombocytopenia and Thrombosis","value":6.35e-05,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13279","display_name":"Safe Handling of Antineoplastic Drugs","value":3.51e-05,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12708","display_name":"Economic and Financial Impacts of Cancer","value":3.11e-05,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","value":1.96e-05,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10746","display_name":"Platelet Disorders and Treatments","value":1.39e-05,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"x_concepts":[{"id":"71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","score":0.9606000185012817},{"id":"177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","score":0.5192000269889832},{"id":"2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","score":0.430400013923645},{"id":"121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","score":0.37940001487731934},{"id":"126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","score":0.3001999855041504}],"counts_by_year":[{"year":2025,"works_count":5,"oa_works_count":2,"cited_by_count":3},{"year":2026,"works_count":3,"oa_works_count":1,"cited_by_count":1}],"display_name_alternatives":["Mia Lynch"],"block_key":"m lynch","works_api_url":"https://api.openalex.org/works?filter=author.id:A5117527428","awards_count":0,"awards_api_url":"https://api.openalex.org/awards?filter=investigators.author.id:A5117527428","updated_date":"2026-11-16T12:53:42","created_date":"2025-05-14T00:00:00"}
